HI SR101

Urges the U.S. Food and Drug Administration, U.S. Surgeon General, and Hawaii's congressional delegation to consider adding warning labels to products containing oxybenzone addressing human health risks.

Cites research findings linking oxybenzone to hormone disruption, estrogen buildup, accumulation in body tissues, Hirschsprung's disease in utero, and transfer through breast milk.

Notes the FDA's most recent safety evaluation of oxybenzone was in 1999 and current labeling requirements do not include warnings about oxybenzone-related health harms.

States no current standard exists for safe oxybenzone levels in the body and no special protections apply to personal care products marketed to women, pregnant mothers, or children.

Directs certified copies of the resolution be sent to the FDA Commissioner, U.S. Surgeon General, Hawaii's congressional representatives, and state health and consumer affairs directors.